Background: Although genital prolapse and carcinoma of the uterine cervix are not rare event, their association is very uncommon. We report a case of this association.Case presentation: A-79-year-old female presented with 11 months history of post-menopausal bleeding, pelvic pain and sensation of heaviness which was increasing in intensity over than 8 months. Physical assessment showed a large genital prolapse third degree and ulcerous and necrotic lesion at the lower part prolapse. Histopathological examination of cervical biopsies revealed well differentiated and invasive squamous cell carcinoma. She was staging according to the International Federation of Gynecology and Obstetrics staging system 2009 as FIGO IIIB. The patient was treated by palliative chemotherapy. After 3 months, the patient died. Conclusion:Genital prolapse with cervical carcinoma is a rare association. In fact, it is necessary to individualize the optimal treatment for each patient to improve life quality and the prognosis.
Background: In 2018, Morocco recorded more than 52,783 new cases of cancer and more than 32,962 cases of death (IARC, 2018). Cancer is always accompanied by socially constructed, differentiated and contingent interpretations and practices according to the socio-cultural and religious characteristics of each region. The aims of this study is describing the evolution of the socio-cultural and religious aspects of Moroccan cancer patients followed at the National Institute of Oncology (NIO) of RABAT between 2010 and 2020.Methods: We have prospectively studied all cancer cases diagnosed at the National Oncology Institute (NIO), Rabat in 2019. We have collected 1102 cases. The data collected was compared with the results of the study carried out in 2010 (1600 cases). Statistical analysis has been assessed by SPSS 20 software and the correlations between socio-cultural characteristics were examined using a chisquare test.Results: from a socio-economic point of view, almost all patients claim that cancer is a costly disease as well as a disease that leads to a drop in income and the inevitable impoverishment of Moroccan patients. The illiteracy rate is higher than in subsequent studies 42.4%. On the psychological level, the damage to body image has a negative impact on the marital relationship. The number of female patients who are victims of spousal divorce and separation is very high. Damage to body image (alopecia) can lead to stigmatizing behaviour. Concerning the spiritual aspect, in the Arab-Berber-Muslim culture, the impact of the occurrence of cancer is very particular, and the repercussions are assessed differently depending on the degree of conviction. for practicing believers, cancer is considered a divine trial, but for non-practicing believers, cancer is regarded as a divine punishment coming from outside. New behaviours reported by this research concern the use of ROKIA as an anti-cancer remedy, 42% of patients use ROKIA.Conclusion: It is important to take these data into account in the therapeutic management of patients in order to better relieve them, which sometimes proves difficult for the healthcare team. The main relief seems to come from the deep religious beliefs that help.
Introduction: To determine the proportion and the reasons which lead to palliative treatment in patients initially a candidate for concomitant chemoradiotherapy (CCRT). Methods: A retrospective study including patients followed for locally advanced lung cancer newly diagnosed from April 1, 2016, to 12/31/2017 in the radiotherapy department of the National Oncology Institute who received palliative treatment. Results: We collected 52 patients out of a total of 225 stage III patients (23%) followed by lung cancer candidates for CCRT who had undergone palliative treatment. The mean age in our series was 61.23 years [22-81] with 86% male. The majority of patients (71%) had Performance Status (PS) ≤ 2. Histological confirmation was obtained by pathological examination in all our patients. It was an adenocarcinoma (ADK) in 54% of cases; squamous cell carcinoma in 46% of cases. The reasons for palliative treatment were mainly due to dosimetric constraints: large tumor volume 22/52 (42%); the tumor location close to the bone marrow in 15 of 52 (29%) patients; and general Performance Status impairment (29%) in 15 of 52 patients. Palliative treatment consisted of palliative chemotherapy in 37 of 52 patients (71%), among whom 19 (51%) were stable after 2 months of chemotherapy, in palliative dose chest radiotherapy on the pulmonary parenchyma and/or mediastinum in 10 of 52 (19%) patients, and supportive care in 5 (10 %) patients. We observed 40/52 (77%) cases of stationary course, 04/52 (8%) cases of progress to metastases, and 08/52 (15%) deaths before radiotherapy. Conclusion: A large proportion of patients followed for locally advanced non-metastatic lung cancer are not eligible for curative treatment. The reasons for the palliative treatment of patients followed for lung cancer candidates for CCRT are variable but for a large proportion of patients due to the deterioration of their state of health during their diagnostic journey. Hence, there
All patients received whole pelvis irradiation to the primary tumor and pelvis lymph nodes to a dose of 46 Gy in 2 Gy per fraction. A parametrial boost (10 Gy additional in 2 Gy per fraction) was provided if parametrial infiltration is still persistent. A lymph node boost (14-20 Gy additional in 2 Gy per fraction) was provided if lymph node enlargement was diagnosed by CT.Concurrent chemotherapy is based in cisplatin at a dose of 40 mg/m² per week (maximum dose of 70 mg/m²). Complete blood count, blood
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.